Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity
Open Access
- 3 February 2026
- journal article
- review article
- Published by Wiley in Advanced Science
- Vol. 13 (14) , e18547
Abstract
Chimeric antigen receptor (CAR)‐T cell immunotherapy has revolutionized the paradigm in hematological malignancies. However, its efficacy in treating solid tumors remains limited because the immunosuppressive tumor microenvironment (ITME) seriously blocks T cell activation, infiltration, and proliferation. Cytokines, driving potent assisted function by enhanced T cell expansion, persistence, and direct tumor cell killing, have long been acknowledged as promising candidates combined with CAR‐T cells to improve treatment outcomes. Despite their preclinical success, significant toxicity occurs in up to one‐third of patients induced by powerful immune‐mediated cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS). In these cases, the risk‐benefit unbalance is less advantageous for advanced cancer therapies, appealing for a profound understanding of pathophysiological mechanisms of CRS and ICANS, as well as improved management of regulating cytokine production. In this review, we first provide an overview of activation and cytotoxic mechanisms of CAR‐T cells. Second, obstacles to CAR‐T cells in the ITME are introduced in detail. Third, the advanced design of CAR‐T engineered cytokines, coupled with current research progress, is described. Furthermore, pathophysiology and clinical features of CRS and ICANS are described in detail. Lastly, prevention and/or intervention approaches of the two above‐mentioned toxicities are emphasized both for developing novel therapeutics and maximizing the benefit of patients.Keywords
Funding Information
- National Natural Science Foundation of China (82473876)
- National Natural Science Foundation of China (82173770)
- Shanghai Jiao Tong University (YG2026QNB26)
- Shanghai Jiao Tong University (YG2025QNA36)
- Shanghai Jiao Tong University (P2024001)
This publication has 205 references indexed in Scilit:
- From Multi‐Omics to Visualization and Beyond: Bridging Micro and Macro Insights in CAR‐T Cell TherapyAdvanced Science, 2025
- Oxidized mRNA Lipid Nanoparticles for In Situ Chimeric Antigen Receptor Monocyte EngineeringAdvanced Functional Materials, 2024
- Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing StrategiesAdvanced Science, 2023
- Engineering chimeric antigen receptor T cells for solid tumour therapyClinical and Translational Medicine, 2022
- VEGFR2 as a target for CAR T cell therapy of Ewing sarcomaPediatric Blood & Cancer, 2020
- Recent advances of microneedles for biomedical applications: drug delivery and beyondActa Pharmaceutica Sinica B, 2019
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- CAR T-cell bioengineering: Single variable domain of heavy chain antibody targeted CARsAdvanced Drug Delivery Reviews, 2019
- Regulated Apoptosis of Genetically Modified Hematopoietic Stem and Progenitor Cells Via an Inducible Caspase-9 Suicide Gene in Rhesus MacaquesStem Cells, 2014
- Tyrosine hydroxylase and regulation of dopamine synthesisArchives of Biochemistry and Biophysics, 2011